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Abstract
Respiratory syncytial virus (RSV) is the leading cause for respiratory illness that requires
hospitalization in infancy. High levels of maternal antibodies can protect against RSV infec-
tion. However, RSV-infected infants can suffer from severe disease symptoms even in the
presence of high levels of RSV-specific antibodies. This study analyzes several serological
characteristics to explore potential deficiencies or surpluses of antibodies that could relate
to severe disease symptoms. We compare serum antibodies from hospitalized patients who
suffered severe symptoms as well as uninfected infants. Disease severity markers were
oxygen therapy, tachypnea, oxygen saturation, admission to the intensive care unit and
duration of hospitalization. Antibodies against RSV G protein and a prefusion F epitope cor-
related with in vitro neutralization. Avidity of RSV-specific IgG antibodies was lower in RSV-
infected infants compared to uninfected controls. Severe disease symptoms were unrelated
to RSV-specific IgG antibody titers, avidity of RSV-IgG, virus neutralization capacity or titers
against pre- and postfusion F or G protein ectodomains and the prefusion F antigenic siteØ.
In conclusion, the detailed serological characterization did not indicate dysfunctional or epi-
tope-skewed composition of serum antibodies in hospitalized RSV-infected infants suffering
from severe disease symptoms. It remains unclear, whether specific antibody fractions
could diminish disease symptoms.
Introduction
Human respiratory syncytial virus (RSV) infections are a major burden for infants [1]. The
symptoms of RSV infection range from a common cold to severe bronchiolitis and
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pneumonia. Children below 3 months of age are at risk for developing severe symptoms that
require admission to the hospital, whereas the vast majority shows only mild disease [2].
Early in life, the infant’s immune system relies mostly on innate immunity and the pres-
ence of maternal, transplacentally transferred immunoglobulin G (matAbs). Consistently,
high levels of RSV-specific matAbs in the cord blood are reported to delay the time point of
primary RSV infection [3, 4]. Intriguingly, primary infections occur even though high levels
of matAbs are present. This raises the question to what extent serum antibodies play a role in
infants suffering from severe symptoms during RSV infection and whether antibodies are
any different from those of infants with a mild course of disease or uninfected controls. To
answer these questions, we investigated whether properties of matAbs such as the level of
prefusion F protein-specificity or levels of non-neutralizing antibodies, could relate to sever-
ity of disease.
Here, we studied the properties of anti-RSV IgG in plasma of infants that were hospitalized
with an acute RSV-infection before 3 months of age. Antibodies observed in a peer group of
uninfected individuals represent a base line for: (1) RSV-IgG antibody titers, RSV-IgG avidity,
and neutralization capacity, (2) antibody titers against G protein, prefusion F protein, postfu-
sion F protein and (3) antibody titers against prefusion antigenic site Ø and postfusion anti-
genic site I. The composition of antibodies and/or their combination with properties might
represent a signature that is typical for severe RSV disease. We analyzed the antibodies for a
correlation with multiple severity parameters, including oxygen therapy, age, respiratory rate,
transcutaneous oxygen saturation, admission to an intensive care unit and duration of hospi-
talization. A better understanding of how antibody properties relate to disease progression is
essential to develop safe and effective immunization strategies.
Materials and Methods
Study design
Hospitalized children below 3 months of age with PCR-confirmed RSV infections were
included during 2011–2013. Within 24 h after admission, a blood sample was taken. Patients
with congenital heart or lung disease, immunodeficiency or glucocorticoid use and infants
born at a gestational age below 35 weeks were excluded. For primary analyses, patients were
classified into two severity groups based on the necessity for oxygen therapy. For secondary
analyses, additional disease severity parameters were used to categorize patients: the presence
of tachypnea, transcutaneous oxygen saturation (93% or <93%), admission to an intensive
care unit and duration of hospitalization. The correlation with age was investigated for all anal-
yses to determine whether age would be a potential confounding factor. Infants below 3
months of age requiring surgery for an inguinal hernia repair were included as healthy, unin-
fected controls. Nasopharyngeal aspirates from all uninfected individuals were RSV negative.
The study protocols were approved by the Regional Committee on Research involving Human
Subjects Arnhem-Nijmegen (serving as the IRB) and were conducted in accordance with the
principles of the Declaration of Helsinki. Written informed consent was obtained from the
parents of all children.
Plasma collection
Coagulation of blood samples was prevented by sodium heparin (BD Vacutainer). After centri-
fugation at 800 x g, the plasma fraction was diluted with an equal volume of phosphate-buff-
ered saline (PBS) and stored at -80˚C.
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Culture of virus and neutralization assay
Recombinant RSV-A2 expressing green fluorescent protein (rgRSV) was kindly provided by
Dr. Peeples and cultured on HeLa cells as described previously [5]. RSV was purified by ultra-
centrifugation over a 30% sucrose layer for 1.5h at 20.000 x g. RSV was quantified by end point
titration assays on HeLa cells.
Recombinant RSV-X expressing green fluorescent protein (RSV-X) has been described
earlier as E1-rRSV_X [6]. RSV-X is a more recent clinical isolate of genotype GA2 with
98.5% amino acid sequence identity with RSV-A2 F protein and 86.2% amino acid sequence
identity with RSV-A2 G protein. A derivative of recombinant RSV-X that is lacking the G
protein was generated by replacing the G protein reading frame by a gene encoding green
fluorescent protein (RSV-X-dG) [7]. RSV-X and RSV-X-dG (Dutch genetically modified
organism license IG-99-210) were propagated in Vero cells (CCL-81, American Type Culture
Collection) using Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies) supple-
mented with 5% FCS and Pen Strep Glutamine (Life Technologies). The cell culture superna-
tants were concentrated by polyethylene glycol-6000 precipitation and stored with 10%
sucrose. Virus titration by end point dilution and plaque reduction neutralization assays
were performed as described earlier [6]. The 50% plaque reduction neutralization titers
(PRNT) were normalized using a correction factor derived from the intra-assay variation of
the WHO513 standard (BEI Resources) and half maximal inhibitory concentrations calcu-
lated by fitting a non-linear curve (GraphPad Prism).
RSV-specific IgG titer and avidity ELISA
RSV-specific IgG concentrations in plasma samples were determined by ELISA. ELISA
plates were coated with rgRSV at a concentration of 2 x 105 U/ml in PBS or PBS as negative
control. Plates were washed with PBS containing 0.05% Tween-20 and blocked with PBS
containing 1% BSA (Sigma-Aldrich). Plasma samples were incubated for 2 h at room tem-
perature (RT). After washing, plates were incubated with alkaline phosphatase (AP)-conju-
gated anti-human IgG in PBS containing 1% BSA for 2 h (1:10,000; Southern Biotech).
Detection of AP activity was performed with 10 mM diethanolamine with 0.5 mM MgCl2
using an ELISA plate reader. Optical density at 450 nm wavelength (OD) from PBS-coated
wells was subtracted from parallel samples coated with RSV. OD values from serial dilutions
of healthy adult pooled plasma ranging 1:10 to 1:10,240 were used as standard to calculate
arbitrary units (AU). To determine the IgG avidity of RSV-specific antibodies, wells were
treated with sodium thiocyanate (NaSCN, 2 mM) for 10 min to weaken antibody binding
and compared to untreated wells [8]. The IgG avidity index was calculated as follows:
(RSV-IgG titer without NaSCN (AU) / RSV-IgG titer with NaSCN (AU) 100).
Recombinant RSV F and G ELISA
Expression constructs, production, and purification of the postfusion F ectodomain (Fwt,
called postfusion F protein hereafter), the trimeric, furin cleavage site-mutated, heptad repeat
B domain-deleted, prefusion F ectodomain (Flys.ΔHRB-GCN, called prefusion F protein
hereafter), and a tetrameric subtype A RSV G ectodomain (residues 64 to 298) have been
described previously [9–11]. The antibody response to RSV F or GA was determined using
ELISA. NUNC multisorp plates were coated with 25 ng of recombinant protein at 4˚C over-
night. After washing with PBS containing 0.05% Tween-20, wells were blocked with 3% BSA
in PBS containing 0.1% Tween-20 at RT. Two-fold serial dilutions of human patient plasma
in blocking buffer were incubated for 1h at RT. After washing, antibodies were labeled with
HRP-conjugated goat anti-human IgG (ITK Southern Biotech) for 1h at RT. HRP activity
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was detected by tetramethylbenzidine substrate (BioFX). The IgG titer for RSV F or G were
determined by calculating the corresponding dilution at OD = 1. Antibody response against
antigenic site Ø and I was assessed by competition ELISA as previously described [11]. Two-
fold serial dilutions of plasma samples or non-labeled monoclonal antibodies (D25 directed
at the specific prefusion F antigenic site Ø, and 131-2a directed at a specific postfusion F anti-
genic site I) in blocking buffer were added and incubated for 1h at RT. After washing, wells
were incubated with 0.6 μg/ml biotin-D25 or 0.2 μg/ml biotin-131-2a to enable binding to
prefusion F after preincubation with the diluted plasma samples. After 1h at RT, the biotiny-
lated antibodies were labeled with 1 μg/ml HRP-conjugated Streptavidin (Thermo Scientific)
and detected by adding tetramethylbenzidine substrate (BioFX) using an ELISA plate reader
(EL-808, Biotek). Wells incubated with biotinylated antibodies alone represent uncompeted,
positive controls and wells blocking buffer alone served as negative control. Percentage inhi-
bition was calculated for every dilution using the following equation: (OD biotinylated MAb
—OD plasma samples) / OD biotinylated MAb X 100. Using a nonlinear 4-parameter fit
curve analysis (GraphPad) the inhibition titer for each plasma samples were determined as
the plasma dilution that resulted in 25% inhibition of D25 or 15% inhibition of 131-2a
binding.
Statistical analysis
Normality tests were performed on all parameters using the Shapiro-Wilk normality test and
showed non-parametric distribution. Comparison between two groups was analyzed by two-
tailed Mann-Whitney U test and comparison between more than two groups was analyzed by
the Kruskall-Wallis test and if significant followed by two-tailed Mann-Whitney U test. Spear-
man correlation test was used for correlation tests. Tests were considered significant if P<
0.05. All statistical analyses were done with GraphPad Prism.
Results
Study population
Plasma IgG from thirty-three hospitalized RSV patients was compared to eleven uninfected
infants. In our primary analysis, the distinction between severe or moderate RSV disease is
determined by whether or not patients received oxygen therapy. Medical doctors make the
decision to hospitalize patients based on most severe symptoms that indicate oxygen therapy
or on moderate symptoms in combination with other indicators, for example frailty or age,
but not requiring oxygen. Consistent with more severe disease, the group that received oxygen
was hospitalized for a longer period, as compared to RSV-infected infants without oxygen
(Table 1). Gender, gestational age, presence of breastfeeding and presence of parental smoking
were comparable between all groups (Table 1). Only children below three month of age were
considered for this study. The group of uninfected infants was slightly older and had a lower
birth weight compared to the RSV-infected groups (Table 1). There was no significant differ-
ence in age and duration of symptoms before hospitalization between RSV-infected infants
with or without oxygen therapy.
Level and avidity of RSV-specific IgG in infant sera
Age is correlated with a decay of matAbs and young age is a risk factor for severe RSV disease
[12]. In this study, we observed no correlation between age at RSV infection and the levels of
RSV-specific IgG (Fig 1A). Moreover, there was no significant difference in RSV-IgG levels
between RSV patients and healthy children (Fig 1B). Next, we asked how antibody levels relate
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to severity of disease. We observed similar levels of RSV-specific IgG in RSV-infected children
with or without oxygen therapy (Fig 1C). In addition, similar serum RSV-IgG levels were
found when comparing other measures of severity (Table 2). The presence of low-avidity RSV-
specific IgG enhances disease symptoms in animal models [13]. RSV-specific IgG in plasma
from RSV-infected infants had a lower RSV-IgG avidity compared to healthy controls, respec-
tively 45 [41–51] versus 55 [48–68] (Fig 1D). However, no difference in RSV-IgG avidity was
observed when categorizing RSV patients based on oxygen therapy or other disease severity
measures (Fig 1E and Table 2).
RSV neutralization capacity of infant sera
Next, we investigated whether the RSV neutralization capacity in vitro relates to RSV infec-
tion or severity of disease. We determined the capacity of patient plasma to neutralize infec-
tion by RSV-X and the G protein-deficient RSV-X-dG. Plasma from healthy controls and
RSV-infected infants neutralized RSV-X and RSV-X-dG to a similar extent (Fig 2A and 2C).
Also, the median PRNT against both viruses was similar between RSV-infected infants with
or without oxygen therapy (Fig 2B and 2D). In addition, no difference in neutralization of
RSV-X and RSV-X-dG was observed when categorizing RSV-infected infants based on other
disease severity parameters (Table 2). Furthermore, we analyzed whether the contribution of
anti-G antibodies to neutralization was different between infant groups. To that end, ratios
were calculated from the PRNT using RSV-X and RSV-X-dG. Average PRNT ratios of 0.9
indicated that 10% of the neutralizing activity could be contributed by anti-G antibodies (Fig
2E). These average PRNT ratios were significantly different from 1, which would occur if
RSV-X and RSV-X-dG were neutralized equally well. A similar PRNT ratio of 0.9 was
observed when comparing RSV-infected infants based on oxygen therapy and healthy infants
(Fig 2E). The functionality of this assay was verified by measuring the ratio of RSV-X and
RSV-X-dG neutralization by palivizumab, a monoclonal antibody that neutralizes RSV by
binding only to the F protein. Thus, palivizumab is independent of the absence or presence
of the G protein. Correspondingly, the ratio of PRNT for RSV-X and RSV-X-dG for palivizu-
mab was 1.01.
Table 1. Study population.
Healthy (n = 11) No oxygen (n = 11) Oxygen (n = 22) P value
Age [days ± IQR] 68 [61–80] 58 [36–66] 39.5 [23–70] <0.05*
Male gender (%) 9 (82) 6 (55) 11 (50) NS
Gestational age [wk ± IQR] 37.3 [34.5–39.0] 39.4 [37.3–40.4] 38.6 [36.9–39.9] NS
Birth weight [kg ± IQR] 2.6 [2.13–3.01] 3.16 [2.79–3.62] 3.27 [2.96–3.97] <0.05#
Breastfeeding (%) 6 (55) 8 (73) 13 (59) NS
Parental smoking (%) 0 (0) 0 (0) 2 (9) NS
Symptomatic [days ± IQR] NA 3.0 [3.0–4.0] 3.5 [2.0–5.0] NS
Duration hospitalization [days ± IQR] NA 3.0 [2.0–6.0] 10.0 [8.0–11.3] <0.001+
Plasma from infants with RSV infections and healthy controls were included and divided by disease severity based on oxygen therapy. Values are depicted
as medians ± interquartile range (IQR) or number with percentage for categorical data. Testing was performed with Kruskall-Wallis and if significant followed
by two-tailed Mann Whitney U test.
* Healthy versus no oxygen p<0.05, healthy versus oxygen p<0.01, oxygen versus no oxygen NS.
# Healthy versus no oxygen p<0.05, healthy versus oxygen p<0.05, oxygen versus no oxygen NS.
+ oxygen versus no oxygen <0.001.
doi:10.1371/journal.pone.0170877.t001
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RSV-specific IgG against viral surface antigens
An excess of anti-G antibodies have been linked with the failure of the formalin-inactivated
RSV vaccine in the 1960s and enhanced disease in mice [14, 15]. Also, antibodies specific for
the postfusion F protein seem not to contribute to RSV neutralization [16]. We tested whether
antibodies against individual antigens would correlate with disease severity. The levels of anti-
gen-specific IgG present in plasma were determined using soluble, recombinant G protein,
pre- and postfusion F protein ectodomains in ELISA. Median antibody levels against G protein
were comparable in plasma derived from healthy infants and RSV infections (Fig 3A). Simi-
larly, we did not find a difference of antibody levels against pre- or postfusion F proteins
between healthy infants and RSV-infected infants (Fig 3C and 3E). The same was true for
median antibody levels when categorizing RSV infections based on oxygen therapy or other
disease severity parameters (Fig 3B, 3D, 3F and Table 2). To investigate whether the balance
between different antibodies is associated with disease severity, we analyzed the difference
between prefusion F and G-specific antibodies as well as pre- and postfusion F–specific anti-
bodies by subtracting antibody levels against G protein or postfusion F protein from those
Fig 1. RSV-specific IgG titer and RSV-IgG avidity do not correlate with disease severity. RSV-specific IgG levels in plasma of infants was
determined by ELISA using virus particles. RSV-IgG avidity was assessed by supplementing NaSCN during ELISA. (A) RSV-specific IgG levels were
displayed versus age. (B-C) Median RSV-specific IgG levels (± IQR) were compared between healthy and RSV-infected infants as well as between RSV
patients with and without oxygen therapy. (D-E) Median (± IQR) avidity of RSV-IgG in healthy infants was compared to RSV-infected infants or between
RSV patients with or without oxygen therapy. Associations were assessed by Spearman correlation test. Statistical analyses employed Mann Whitney U
test. (**P<0.01).
doi:10.1371/journal.pone.0170877.g001
Maternal Antibodies during RSV Infection
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against prefusion F protein. The relative abundance of RSV-antigens was comparable in all
groups (Fig 3G and 3H), thus no symptom-related antibody composition was identified.
RSV-specific IgG against a prefusion F epitope
Antibodies against prefusion F protein have received much attention recently, because they
correlate best with RSV neutralization in vitro. We refined our analysis to detect antibodies
against epitopes that discriminate between pre- and postfusion F [16, 17]. Sera from healthy
and RSV-infected infants were titrated to compete with the monoclonal antibody D25 for pre-
fusion-specific antigenic site Ø or with the monoclonal antibody 131-2a for the postfusion-
specific epitope I [9, 11, 16, 18]. The median competition titers were similar between healthy
infants and RSV-infected infants for D25 (Fig 4A) and for 131-2a (Fig 4C). We observed no
difference in D25 competition or 131-2A competition when categorizing RSV infections based
Fig 2. RSV neutralization does not correlate with severity of disease. 50% plaque reduction neutralization titers (PRNT) were determined against
RSV-X and RSV-X-dG, the latter is lacking the G protein. (A-B) Median (± IQR) PRNT against RSV-X were compared between healthy and RSV-infected
infants as well as between RSV patients with and without oxygen therapy. (C-D) Median (± IQR) PRNT against RSV-X-dG were compared between
healthy and RSV-infected infants as well as between RSV patients with or without oxygen therapy. (E) The PRNT against RSV-X was divided the PRTN
against RSV-X-dG, so that values below 1.0 indicate a contribution of anti-G antibodies to the neutralization. The median (± IQR) ratio was compared
between plasma from healthy infants and RSV patients with or without oxygen therapy and all were significantly different from 1.0. Statistical analyses
employed Mann Whitney U test for comparison between two groups and Kruskall-Wallis for comparison between more than two groups. (*P<0.05,
**P<0.01).
doi:10.1371/journal.pone.0170877.g002
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on oxygen therapy (Fig 4B, 4D and Table 2). A previous study showed that prefusion F pro-
tein-specific antibodies determine the neutralization activity of seroconverted individuals
older than 6 years of age [16]. To assess whether this is represented in our measurements of
RSV-specific matAbs, we considered the relationship between antigen- and epitope-specific
antibody titers and neutralizing capacity (PRNT). Antibodies against postfusion F and 131-2a
competition titers represent a negative control and were not associated with neutralization
(Fig 5A and 5B). Prefusion F-specific antibodies and D25 competition titers correlated with
PRNT (Fig 5C and 5D). Furthermore, antibody titers against G protein also correlated posi-
tively with PRNT (Fig 5E).
Discussion
Infants encounter primary RSV infections even though matAbs are present in their blood. We
investigated whether individual serologic properties of antibodies or any signature combina-
tions thereof would be related to the observed disease symptoms. Our results indicate that (i)
disease severity is not associated with differences in RSV-specific IgG titers, RSV-IgG avidity,
or virus neutralization and (ii) plasma titers of RSV-specific IgG against the G protein and the
prefusion F protein correlate with neutralizing capacity. In addition, (iii) IgG titers directed
against the G protein, prefusion F protein, postfusion F protein, F-antigenic siteØ and site I,
or any combination of thereof could not be associated with severity of symptoms.
Plasma from infants below 3 months of age was selected because of the high incidence of
severe RSV infection even though high levels of matAbs are present in this group. Indeed, we
Fig 3. RSV-specific IgG against individual RSV glycoproteins do not correlate with disease severity. RSV glycoprotein-specific antibody levels
were determined by ELISA against recombinant, soluble ectodomains. Median IgG levels (± IQR) were compared between healthy and RSV-infected
infants as well as between RSV patients with and without oxygen therapy. Glycoproteins used for ELISA coating were (A-B) RSV G protein, (C-D)
prefusion F protein, and (E-F) postfusion F protein. (G-H) The relative abundance of antibodies against prefusion F compared to G protein as well as pre-
compared to postfusion F protein were categorized assessed by subtracting their levels. The median (± IQR) difference was compared between plasma
from healthy infants and RSV patients with or without oxygen therapy. No significant differences were observed by Mann Whitney U test for comparison
between two groups and Kruskall-Wallis for comparison between more than two groups.
doi:10.1371/journal.pone.0170877.g003
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Fig 4. RSV-specific IgG against F protein antigenic sitesØ and I not correlate with disease severity. The abundance of antibodies in human infant
plasma that bind to the prefusion F protein antigenic siteØ or the postfusion F protein antigenic site I was determined by competition with site-specific
monoclonal antibodies in ELISA. (A-B) Median (± IQR) IgG titer that blocks 25% binding of D25 (siteØ) were compared between healthy and RSV-
infected infants as well as between RSV patients with and without oxygen therapy. (C-D) Median (± IQR) IgG titer that blocks 15% binding of 131-2A (site
I) were compared between healthy and RSV-infected infants as well as between RSV patients with and without oxygen therapy. No significant differences
were observed by Mann Whitney U test.
doi:10.1371/journal.pone.0170877.g004
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Fig 5. RSV-specific IgG against prefusion F epitope and G protein correlate with neutralization.
Neutralization titers against RSV-X (PRNT) were compared to IgG levels against (A) postfusion F protein, (B) site I
(131-2A competition titer), (C) prefusion F protein, (D) siteØ (D25 competition titer) and (E) G protein. Testing for
correlation was performed with Spearman correlation test.
doi:10.1371/journal.pone.0170877.g005
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found a median RSV neutralization titers of about 1:512 for all infants (Fig 2), which is similar
to what is reported for cord blood in some studies [19, 20]. We omitted age as a confounder
for different severity of symptoms, as the age of RSV-infected infants without oxygen therapy
was comparable to that of oxygen-treated children. A potential limitation of our study is the
difficulty to separate the presence of matAbs from endogenous RSV-induced antibodies of the
infant during infection. With a median onset of disease of three days and the short time
between symptoms and hospitalization, production of endogenous RSV-IgG is improbable.
Moreover, as Dutch newborns in general suffer their first respiratory infection after 3–7
months of age and only 11% of respiratory infections within the first year of life are caused by
RSV, infants in our study most likely experienced a primary RSV infection [21]. Therefore, it
is plausible that we detect matAbs [22]. Our plasma selection facilitates the comparison of anti-
bodies from hospitalized patients with symptoms ranging from moderate to severe. As this is
not a prospective study, the ideal control group of RSV-infected children with mild symptoms
was not available, because blood of these children is not routinely sampled. A common prac-
tice in RSV research is to use age-matched infants as control. One assumes that this group is
not protected and if healthy infants become RSV infected, a vast majority of 98–99% would
develop only mild symptoms [23]. We too, substituted the group with mild disease by the anal-
ysis of antibodies from uninfected infants. This has no significant impact on our findings and
conclusions. The sample size of our control group is relatively small and definitive conclusions
in the context of correlation with infection warrant future studies. Nevertheless, the median
levels of antibody properties are in close proximity with the median levels of RSV-infected
infants. Therefore, it seems unlikely that an addition of more control samples would signifi-
cantly affect our interpretation. Future studies may include mild infections or prospectively
follow healthy infants until RSV infections occurs to investigate the protective effect of RSV-
specific antibodies.
High titers of IgG matAbs against RSV have been inversely associated with prevention of
hospitalization for RSV disease [24], whereas mucosal IgA reduces the propensity to become
infected with RSV [25]. We did not study IgA-mediated prevention of infection, because
RSV-IgA is not transplacentally transferred during gestation. We specifically investigated IgG
antibodies during an acute infection and observed no correlation between RSV-IgG titer or
RSV neutralization and severity of symptoms. Differences in the design of studies investigating
prevention of RSV infection versus prevention of severe disease symptoms in hospitalized
infants may explain the different conclusion. However, our data is in line with some studies
that describe that hospitalization during RSV disease is not correlated to matAb levels [22, 26].
Furthermore, we found RSV-IgG avidity from uninfected infants was significantly higher than
from RSV patients, but was not associated with disease severity. Previous studies in mice sug-
gest that non-neutralizing and low affinity antibodies could contribute to the enhanced pathol-
ogy [13, 14, 27]. The biological relevance of the small but significant differences in RSV-IgG
avidity between uninfected infants and infants with RSV infection should be carefully inter-
preted, because the threshold for antibody avidity to be efficacious during RSV infections is
currently unknown. These results should be validated with a prospective study to determine
the association of avidity and the protection against severe RSV infections in infants.
As global antibody properties such as titers and neutralization capacity did not correlate
with severity of disease, we analyzed whether this was also the case for antibodies against
specific RSV antigens. Anti-G protein antibodies have been suggested to facilitate immuno-
pathology in children [14, 27]. In contrast, RSV neutralizing antibodies are usually directed
against prefusion F and can be administered as prophylaxis [16, 28]. By comparing the
PRNT of patient plasma against full length RSV-X and RSV-X-dG, which lacks the G gene,
we observed that anti-G protein antibodies contribute to neutralization in vitro. This is
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supported by a positive relationship between anti-G protein antibody titers and PRNT.
However, the median anti-G antibody titers were similar across all infant sera, regardless of
disease and severity. Our serology using RSV A-derived materials does not account for
potential impact of the RSV genotype on disease. We believe this is not affecting the inter-
pretation of our results, because only a single serotype for RSV exists. Plasma antibodies
from human infants prior to RSV infection, i.e. maternal antibodies, generally show very
similar activity against major RSV subtypes regarding the conserved F protein but also the
more variable G protein [29]. Moreover, different RSV genotypes have not been convinc-
ingly or continuously linked to the epidemiology of RSV outbreaks. We next asked whether
the ratios between antibodies against G, pre- and postfusion F would represent a specific sig-
nature in severely sick infants compared to mildly sick children and controls. We found that
the balance between prefusion F and other antibodies was similar in all infants and indepen-
dent of their disease severity.
Recent data suggests that especially antibodies targeting the prefusion F protein epitope Ø
efficiently neutralize RSV [30, 31]. To determine whether infants suffering from severe disease
symptoms have different epitope Ø binding antibodies compared to controls, we analyzed
patient plasma from all groups in a competition assay with D25 and 131-2A. As we did not
find any difference, we argue that sera from mildly sick RSV patients have average epitope Ø-
specific antibody titers just like children with severe symptoms. We did observe an association
between recognition of the D25 epitope and the PRNT of matAbs, like previously shown in
seroconverted individuals above 6 years of age [16]. We tested for this prefusion F specific anti-
body because it is the focus of current therapeutic developments. We note that there are more
prefusion epitopes that could theoretically correlate with disease.
Apart from interacting with viral antigens on virions, antibodies also have Fc region-medi-
ated immunological functions during natural infection. For example, antibodies form immune
complexes that can reshape the cytokine and chemokine response of human immune cells [32,
33] or facilitate complement deposition. We did not study antibody effector functions that
could relate to severity of disease.
In conclusion, this study investigated the properties of naturally occurring RSV-specific
matAbs hoping to provide clues about a specific signature of antibodies that is needed to
prevent severe RSV infections. Our detailed characterization did not find any difference
in matAbs between infants with severe RSV disease symptoms, controls with mild RSV dis-
ease and uninfected infants. This means that the matAb properties we studied do not indi-
cate whether a child would be protected from severe symptoms. It will be very important to
find such properties or signatures in order to design effective vaccination strategies in the
future.
Supporting Information
S1 Table. Supporting information depicting all individual data.
(XLS)
Acknowledgments
We thank Wouter F. van Leeuwen and Jolande Boes for technical support and Marie¨tte Las
and Fabian Brouwer for their help in the study. We thank all children and their parents for
their collaboration.
Maternal Antibodies during RSV Infection
PLOS ONE | DOI:10.1371/journal.pone.0170877 January 30, 2017 13 / 16
Author Contributions
Conceptualization: JJ OW IW IA RG TG WL MJ CH GF.
Data curation: IA.
Formal analysis: JJ OW.
Funding acquisition: OW RG TG WL MJ CH GF.
Investigation: JJ OW IW.
Project administration: RG TG WL MJ CH GF.
Resources: IA.
Supervision: RG TG WL MJ CH GF.
Validation: JJ OW IW IA.
Visualization: JJ OW.
Writing – original draft: JJ OW.
Writing – review & editing: JJ OW TG WL MJ CH GF.
References
1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower
respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-
analysis. Lancet. 2010; 375(9725):1545–55. doi: 10.1016/S0140-6736(10)60206-1 PMID: 20399493
2. Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics. 2010; 125
(2):342–9. doi: 10.1542/peds.2009-2092 PMID: 20100768
3. Chu HY, Steinhoff MC, Magaret A, Zaman K, Roy E, Langdon G, et al. Respiratory syncytial virus trans-
placental antibody transfer and kinetics in mother-infant pairs in Bangladesh. The Journal of infectious
diseases. 2014; 210(10):1582–9. Epub 2014/06/07. doi: 10.1093/infdis/jiu316 PMID: 24903663
4. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for
infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J
Pediatr. 1981; 98(5):708–15. PMID: 7229749
5. Vissers M, Hartman Y, Groh L, de Jong DJ, de Jonge MI, Ferwerda G. Recognition of Streptococcus
pneumoniae and muramyl dipeptide by NOD2 results in potent induction of MMP-9, which can be con-
trolled by lipopolysaccharide stimulation. Infect Immun. 2014; 82(12):4952–8. doi: 10.1128/IAI.02150-
14 PMID: 25183734
6. van Remmerden Y, Xu F, van Eldik M, Heldens JG, Huisman W, Widjojoatmodjo MN. An improved
respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein
expression and automated plaque counting. Virol J. 2012; 9:253. doi: 10.1186/1743-422X-9-253 PMID:
23114196
7. Widjojoatmodjo MN, Boes J, van Bers M, van Remmerden Y, Roholl PJ, Luytjes W. A highly attenuated
recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in
cotton rats. Virol J. 2010; 7:114. doi: 10.1186/1743-422X-7-114 PMID: 20525213
8. Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP. Anti-
body avidity and immunoglobulin G isotype distribution following immunization with a monovalent
meningococcal B outer membrane vesicle vaccine. Infection and immunity. 2002; 70(2):584–90. doi:
10.1128/IAI.70.2.584-590.2002 PMID: 11796586
9. Widjaja I, Rigter A, Jacobino S, van Kuppeveld FJ, Leenhouts K, Palomo C, et al. Recombinant Soluble
Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization
Motif and Is Not Cleaved Displays Prefusion-Like Characteristics. PloS one. 2015; 10(6):e0130829. doi:
10.1371/journal.pone.0130829 PMID: 26107504
10. Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M, Leenhouts K, et al. A protective
and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to
bacterium-like particles. PLoS One. 2013; 8(8):e71072. doi: 10.1371/journal.pone.0071072 PMID:
23951084
Maternal Antibodies during RSV Infection
PLOS ONE | DOI:10.1371/journal.pone.0170877 January 30, 2017 14 / 16
11. Widjaja I, Wicht O, Luytjes W, Leenhouts K, Rottier PJ, van Kuppeveld FJ, et al. Characterization of Epi-
tope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection
and after Vaccination with Formalin-Inactivated RSV. J Virol. 2016; 90(13):5965–77. doi: 10.1128/JVI.
00235-16 PMID: 27099320
12. Wright PF, Gruber WC, Peters M, Reed G, Zhu Y, Robinson F, et al. Illness severity, viral shedding,
and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus.
The Journal of infectious diseases. 2002; 185(8):1011–8. doi: 10.1086/339822 PMID: 11930309
13. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody
affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial
virus disease. Nat Med. 2009; 15(1):34–41. doi: 10.1038/nm.1894 PMID: 19079256
14. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, et al. Dissociation between
serum neutralizing and glycoprotein antibody responses of infants and children who received inacti-
vated respiratory syncytial virus vaccine. J Clin Microbiol. 1986; 24(2):197–202. PMID: 3755730
15. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. Generation of atypical pulmonary
inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein
of respiratory syncytial virus. J Virol. 1996; 70(11):7783–91. PMID: 8892899
16. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, et al. Prefusion F-specific antibod-
ies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015; 7
(309):309ra162.
17. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, et al. Characterization of two antigenic sites
recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human
respiratory syncytial virus. J Gen Virol. 1992; 73 (Pt 9):2225–34.
18. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein
in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85(15):7788–
96. doi: 10.1128/JVI.00555-11 PMID: 21613394
19. Nyiro JU, Sande C, Mutunga M, Kiyuka PK, Munywoki PK, Scott JA, et al. Quantifying maternally
derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.
Vaccine. 2015; 33(15):1797–801. Epub 2015/03/01. doi: 10.1016/j.vaccine.2015.02.039 PMID:
25725445
20. Atwell JE, Thumar B, Robinson LJ, Tobby R, Yambo P, Ome-Kaius M, et al. Impact of Placental Malaria
and Hypergammaglobulinemia on Transplacental Transfer of Respiratory Syncytial Virus Antibody in
Papua New Guinea. The Journal of infectious diseases. 2016; 213(3):423–31. Epub 2015/08/05. doi:
10.1093/infdis/jiv401 PMID: 26238686
21. van der Zalm MM, Uiterwaal CS, Wilbrink B, de Jong BM, Verheij TJ, Kimpen JL, et al. Respiratory path-
ogens in respiratory tract illnesses during the first year of life: a birth cohort study. The Pediatric infec-
tious disease journal. 2009; 28(6):472–6. Epub 2009/06/09. PMID: 19504730
22. Freitas GR, Silva DA, Yokosawa J, Paula NT, Costa LF, Carneiro BM, et al. Antibody response and
avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children. J Med Virol.
2011; 83(10):1826–33. doi: 10.1002/jmv.22134 PMID: 21837801
23. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the Epidemiology
and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western
Countries. Infectious diseases and therapy. 2016; 5(3):271–98. Epub 2016/08/03. doi: 10.1007/
s40121-016-0123-0 PMID: 27480325
24. Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, et al. Respiratory syncytial virus
neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J
Allergy Clin Immunol. 2009; 123(2):398–403. doi: 10.1016/j.jaci.2008.10.043 PMID: 19101023
25. Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, et al. Impaired Antibody-mediated
Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncy-
tial Virus. Am J Respir Crit Care Med. 2015; 191(9):1040–9. doi: 10.1164/rccm.201412-2256OC PMID:
25730467
26. Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, et al. The role of neutralizing antibodies in
protection of American Indian infants against respiratory syncytial virus disease. The Pediatric infec-
tious disease journal. 2008; 27(3):207–12. doi: 10.1097/INF.0b013e31815ac585 PMID: 18277934
27. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered
clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an
inactivated RS virus vaccine. Am J Epidemiol. 1969; 89(4):405–21. PMID: 4305197
28. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, et al. Generation of sta-
ble monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic program-
ming. Nat Med. 2010; 16(1):123–8. doi: 10.1038/nm.2071 PMID: 20023635
Maternal Antibodies during RSV Infection
PLOS ONE | DOI:10.1371/journal.pone.0170877 January 30, 2017 15 / 16
29. Shinoff JJ, O’Brien KL, Thumar B, Shaw JB, Reid R, Hua W, et al. Young infants can develop protective
levels of neutralizing antibody after infection with respiratory syncytial virus. The Journal of infectious
diseases. 2008; 198(7):1007–15. doi: 10.1086/591460 PMID: 18702606
30. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ, et al. A highly stable
prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nature communica-
tions. 2015; 6:8143.
31. McGinnes Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG. Murine immune responses
to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein. J
Virol. 2015; 89(13):6835–47. doi: 10.1128/JVI.00384-15 PMID: 25903340
32. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in
enhanced respiratory syncytial virus disease. J Exp Med. 2002; 196(6):859–65. doi: 10.1084/jem.
20020781 PMID: 12235218
33. Gomez RS, Ramirez BA, Cespedes PF, Cautivo KM, Riquelme SA, Prado CE, et al. Contribution of
Fcgamma receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell acti-
vation by dendritic cells. Immunology. 2016; 147(1):55–72. doi: 10.1111/imm.12541 PMID: 26451966
Maternal Antibodies during RSV Infection
PLOS ONE | DOI:10.1371/journal.pone.0170877 January 30, 2017 16 / 16
